Full-Time

TA Director – Risk Management Lead

Multiple Therapeutic Areas

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$156k - $296.5k/yr

+ Short-term incentive programs

Waukegan, IL, USA + 1 more

More locations: Irvine, CA, USA

Hybrid

On-site Tue-Thu required; local to Lake County, Illinois or Irvine, California.

Bachelor's, Master's, PharmD, PhD, MD

Category
Biology & Biotech (1)
Required Skills
Power BI
Tableau
Risk Management
Data Analysis
Excel/Numbers/Sheets

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Minimum of a bachelor’s degree in life sciences, healthcare, pharmacy, nursing, or a related field; an advanced degree (Master’s, PharmD, PhD, MD) is strongly preferred.
  • At least 15 years of experience in clinical research, clinical operations, or study/data risk management, with a minimum of 5 years in a leadership or people management capacity.
  • Demonstrated expertise in risk-based quality management (RBQM), including experience applying ICH-GCP E6(R2) risk-based methodology and risk management best practices in clinical development.
  • Direct hands-on experience with portfolio-level risk assessments, Risk Assessment and Mitigation Planning (RAMP), and implementing risk-based modifications across multiple clinical programs/therapeutic areas.
  • Strong knowledge of relevant regulatory guidelines (FDA, EMA, ICH), Good Clinical Practice (GCP), and global health authority requirements for clinical trials.
  • Experience with critical-to-quality (CtQ) elements, protocol design input, and collaboration with evidence strategy teams preferred.
  • Demonstrated success developing, mentoring, and leading teams, preferably in a matrixed global environment.
  • Advanced skills in data analytics, dashboarding, and the use of data visualization tools (e.g., Excel, Power BI, Tableau) for risk oversight and decision-making support.
  • Excellent interpersonal skills; able to communicate complex concepts clearly, persuade stakeholders, and foster cross-functional collaboration.
Responsibilities
  • Drive portfolio-level risk identification and mitigation strategies in partnership with therapeutic area teams, enhancing proactive management of study and program risks.
  • Support and collaborate with the Integrated Evidence Strategy Team (IEST) to embed critical-to-quality elements into protocol design, ensuring data collection is focused on decision-making needs.
  • Lead, develop, and mentor a team of Risk Management Leads, fostering expertise, collaboration, and innovation in risk-based quality management.
  • Oversee the development and execution of therapeutic area risk insights, dashboards, and mitigation plans, promoting a deep understanding of risk drivers and solutions.
  • Ensure robust RAMP (Risk Assessment and Mitigation Plan) processes, tracking accountability and ensuring timely, data-driven risk action planning.
  • Address resource gaps by overseeing RAMP entry work and supporting the implementation of risk-based modifications to the scope of studies assigned to Study Risk Leads (SRLs), advocating for full resource needs where required.
  • Collaborate with cross-functional stakeholders (including Clinical Site Management, Clinical Study Leadership, Data Science, and Compliance) to ensure alignment and consistency in risk management practices.
  • Contribute to the development, standardization, and continuous improvement of risk management best practices, metrics, and training across the organization.
Desired Qualifications
  • Advanced degree (Master’s, PharmD, PhD, MD) strongly preferred.
  • Professional risk management certifications are highly desirable (e.g., ASQ Certified Manager of Quality & Organizational Excellence, Chartered Enterprise Risk Analyst (CERA), Certified Risk Manager (CRM), Professional Risk Manager (PRM), ASQ Risk Management Specialized Credential, or equivalent experience).
  • Experience with critical-to-quality (CtQ) elements, protocol design input, and collaboration with evidence strategy teams preferred.
  • Advanced skills in data analytics, dashboarding, and the use of data visualization tools (e.g., Excel, Power BI, Tableau) for risk oversight and decision-making support.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.